Certara, Inc. CERT

AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "In-Silico Drug Discovery Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global In-Silico Drug Discovery Market to Reach US$6 Billion by 2030 The global in-silico drug discovery market was valued at US$3.3 billion in 2024 and i

AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Informatics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Informatics was estimated at US$4.0 Billion in 2025 and is projected to reach US$8.7 Billion by 2032, growing at a CAGR of 11.9% from 2025

Biosimulation adoption is rising in drug development, driven by AI, personalized medicine, regulatory support and R&D cost savings, with strong opportunities in services and Asia-Pacific.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Biosimulation Technology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Biosimulation Technology was valued at US$3.6 Billion in 2024 and is projected to reach US$8.5 Billion by 2030, growing at a CAGR of 1

On August 4, Certara (NASDAQ:CERT) reported second-quarter 2026 results that told two different stories at once. Software revenue climbed 4% to $48.8 million, and bookings for that segment jumped 9%, yet the company swung to a $6.1 million net loss just a year after posting a small profit. Layered on top of a completed divestiture, […]

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF] ("Cerrado" or the "Company") is pleased to announce that it has closed the previously announced strategic non-brokered private placement financing (the "Private Placement") with Mr. Eric Sprott for aggregate gross proceeds of C$10 million. The Private Placement consisted of the issuance of 4,000,000 units of the Company (the "Units") to an entity owned and controlled by Mr. Sprott at a price of C$2.50 per Uni

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF] ("Cerrado" or the "Company") is pleased to announce that it has entered into an agreement for a strategic non-brokered private placement financing (the "Private Placement") with Mr. Eric Sprott for aggregate gross proceeds of C$10 million. The Private Placement will consist of 4,000,000 units of the Company (the "Units") at a price of C$2.50 per Unit. Each Unit will consist of one common share in the capital o

TORONTO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF] (“Cerrado” or the “Company”) is pleased to announce the appointment of Mr. Chris MacInnis to the position of Vice President, Geology, effective immediately. Mr. MacInnis joined Cerrado as a Director of Geology and Resources in March 2023. Mr. MacInnis is a professional Geologist with over 20 years of experience in mineral resource definition and exploration. Prior to joining Cerrado Gold, Mr. MacInnis was the

In early August 2026, Certara reported second-quarter results showing slightly higher sales of US$93.27 million but a much larger net loss of US$55.27 million, alongside executive reshuffling including the departure of President and Chief Commercial Officer Leif Pedersen and the appointment of Julien Perrier as Chief Commercial Officer and Eric Jahn as Chief Information Officer. At the same time, Certara reaffirmed its 2026 revenue outlook while expanding its share repurchase authorization...

Moby summary of Certara, Inc.'s Q2 2026 earnings call

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results. Second Quarter Highlights from Continuing Operations: Financial results of the Regulatory and Me

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advanc

Optimization Opportunities to be incorporated into the Mont Sorcier Feasibility, resulting in an extended completion date. Key Optimization Focus Areas Include: Enhanced Mine plan to reduce Overall Strip RatioTailing Dam ConstructionCAPEX and OPEX review in light of Ongoing Regional InflationTrade-off in Concentrate Quality vs Premium Price Modest Drill Program set for late Q3 to Enhance Mine Plan by Upgrading additional Resources TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX